Alimera Sciences, Inc.

NasdaqGM:ALIM Stock Report

Market Cap: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Management

Management criteria checks 1/4

Alimera Sciences' CEO is Rick Eiswirth, appointed in Jan 2019, has a tenure of 5.67 years. total yearly compensation is $3.26M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $1.80M. The average tenure of the management team and the board of directors is 2.1 years and 2.3 years respectively.

Key information

Rick Eiswirth

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage18.5%
CEO tenure5.7yrs
CEO ownership0.6%
Management average tenure2.1yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Sep 11

Alimera Sciences: Cheap CVR Optionality

Jul 16

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Jun 18
Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Dec 30
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Oct 13
Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Sep 13
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06
Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11
Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

CEO Compensation Analysis

How has Rick Eiswirth's remuneration changed compared to Alimera Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$3mUS$603k

-US$21m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$974kUS$580k

-US$18m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$890kUS$550k

-US$4m

Sep 30 2021n/an/a

-US$1m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$888kUS$550k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$977kUS$525k

-US$10m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

US$19m

Mar 31 2019n/an/a

US$22m

Dec 31 2018US$831kUS$495k

US$17m

Sep 30 2018n/an/a

US$11m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$23m

Dec 31 2017US$811kUS$425k

-US$22m

Compensation vs Market: Rick's total compensation ($USD3.26M) is above average for companies of similar size in the US market ($USD2.42M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.

CEO

Rick Eiswirth (56 yo)

5.7yrs

Tenure

US$3,261,480

Compensation

Mr. Richard S. Eiswirth, Jr., also known as Rick, served as Interim Chief Financial Officer at Alimera Sciences, Inc. since 2022. He has been President of Alimera Sciences, Inc. since January 1, 2016 until...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Jason Werner
Chief Operating Officerless than a yearUS$1.39m0.0017%
$ 5.1k
Philip Ashman
President of International Operationsless than a yearUS$1.02m0.22%
$ 655.2k
David Holland
Co-Founder21.3yrsUS$541.72k0.35%
$ 1.0m
Elliot Maltz
CFO & Treasurerless than a yearno data0%
$ 0
Christopher Visick
VP, General Counsel & Secretary5.8yrsno datano data
David Dyer
Chief Retina Specialist3.3yrsno data0.0083%
$ 25.1k
Todd Wood
President of U.S. Operationsless than a yearno data0%
$ 0

2.1yrs

Average Tenure

55.5yo

Average Age

Experienced Management: ALIM's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Peter Pizzo
Independent Director14.4yrsUS$186.31k0.00092%
$ 2.8k
Margaret Pax
Directorless than a yearUS$96.42k0%
$ 0
Ross DeMont
Director1.7yrsUS$124.63k0%
$ 0
John Snisarenko
Independent Director5.2yrsUS$172.21k0.018%
$ 55.4k
Michael Kaseta
Independent Director1.5yrsUS$151.70k0%
$ 0
Adam Morgan
Chairman of the Board1.5yrsUS$165.75k0%
$ 0
Erin Parsons
Director2.8yrsUS$172.52k0%
$ 0

2.3yrs

Average Tenure

53.5yo

Average Age

Experienced Board: ALIM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/18 04:16
End of Day Share Price 2024/09/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alimera Sciences, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.